| INTRODUCTION
Infliximab is a monoclonal antibody against tumour necrosis factor (TNF)-a, which has been shown to effectively induce and maintain long-term clinical remission in Crohn's disease (CD) and Ulcerative colitis (UC) patients.
1,2 Sufficient infliximab serum levels (between 3 and 7 lg/mL) have been positively correlated with clinical and endoscopic remission, while the development of antibodies towards the drug has been associated with loss of response to infliximab therapy. [3] [4] [5] [6] Up to 30% of inflammatory bowel disease (IBD) patients show no clinical benefit by the end of induction period (week 14) and are considered primary nonresponders. 7 Several clinical and laboratory factors have been associated with primary nonresponse, including smoking, long disease duration, older age, previous surgery, complicated phenotype and prior failure of another anti-TNF agent. Active inflammation, mirrored by increased C-reactive protein (CRP) and decreased serum albumin levels, has also been associated with unfavourable clinical outcome. 8, 9 The mechanisms underlying primary nonresponse have not been clearly defined so far. It has been proposed that both pharmacokinetic (low serum drug concentrations due to an accelerated clearance of the drug) and non-TNF-driven inflammatory processes (with adequate drug levels) take place. [10] [11] [12] In this study, we aimed to evaluate the association between early induction infliximab and antibodies to infliximab (ATI) levels and primary nonresponse, with the goal of examining to which extent pharmacokinetic parameters can predict clinical outcome of infliximab induction therapy.
2 | ME TH ODS
| Patient population
This was a retrospective observational study of patients with IBD followed by the Gastroenterology Department of Sheba Medical
Center and treated with infliximab between 2009 and 2016. Fortyfive primary nonresponders to consecutive infliximab induction therapy were detected in our database. Ten patients were excluded due to the lack of available prospective sera throughout induction period (weeks 0, 2, 6). Thus, 35 nonresponders were included in the study and compared with 105 consecutive IBD patients from our database, who responded to infliximab induction therapy (1:3 ratio, primary responders) and had all prospective induction sera available (see found significant on univariate analysis (P < .1) were incorporated into the multivariate models.
The study was approved by the Sheba Medical Center Ethics committee and all patients gave an informed consent to participate.
| Therapeutic drug monitoring
Infliximab serum levels are prospectively analysed for every patient before each infusion at the Sheba medical Center's Gastroenterology laboratory. Infliximab and ATI levels were measured by employing our previously described infliximab ELISA assay. 13 This method has been shown to allow reliable measurement of ATIs even in the presence of adequate levels of infliximab. 14 
| Clinical scores
Clinical response was determined using HBI (Harvey-Bradshaw index) and SCCAI (simple clinical colitis activity index) for Crohn's disease (CD) and ulcerative colitis (UC) patients respectively. [15] [16] [17] Clinical response was defined as drop of ≥3 points of the HBI or SCCAI score, for CD and UC patients respectively. 17 Primary nonresponse was defined as the lack of clinical improvement by the end of induction period (week 14), 7 which necessitated cessation of infliximab therapy. 
| Statistical analysis

| INFLIXIMAB AND ATI LEVELS
Induction trough infliximab and antibodies to infliximab (ATI) levels were compared between the two groups of patients. Both week 2 and week 6 infliximab levels were significantly lower among primary nonresponders than among responders (week 2: median infliximab level 7.2, IQR 9.3-20 lg/mL vs 13.6, IQR 2.1-15.6 lg/mL, respectively, P = .0019; week 6: median infliximab level 2.2, IQR 0.18-5.4 lg/mL vs 9.5, IQR 5.4-17.2 lg/mL, respectively, P < .0001, Figure 1 ). Figure 2A ). Week 6 ATI was significantly more frequent among the primary nonresponders than among primary responders (OR = 6.3, CI 2.6-15.1, P < .0001) while for week 2 ATI, there was only a trend (OR = 2, CI 0.88-4.6, P = .09). Moreover, among those who developed ATI in both groups, their levels were significantly higher among the former than among the latter at both week 2 and week 6 (week 2: median ATI 7.3, IQR 4.4-11.5 lg/mL-eq, vs 3.8, IQR 3-5.6 lg/mL-eq, P = .005. week 6:
median ATI 10.8, IQR 6-23.8 lg/mL-eq, vs 4.4, IQR 2.8-7.2 lg/mLeq, P = .0088, Figure 2B and 2C respectively).
| ROC CURVE ANALYSES
In order to determine cut-offs for infliximab and ATI levels, which would associate best with primary nonresponse and enable early prediction of clinical response to induction, we plotted an AUC curve, for trough drug and ATI levels. Trough infliximab levels below 6.8 lg/mL at week 2 had a sensitivity of 50% and specificity of 86%
for primary nonresponse (AUC = 0.68, P = .002, Figure 3A ). Similarly, among ATI-positive patients, week 2 ATI levels above 4.33 lg/ mL-eq had a 77% sensitivity and 71% specificity for primary nonresponse (AUC = 0.78, P = .0004, Figure 3B ). Similar analyses were performed for week 6 drug and ATI levels: week 6 infliximab levels below 3.5 lg/mL were 68% sensitive and 83.3% specific for primary nonresponse (AUC = 0.78, P < .0001) and positive ATI (>2.5 lg/mLeq, assay's detection threshold) were 55% sensitive and 83.3% specific (AUC = 0.7, P = .01). F I G U R E 1 Week 2 and week 6 infliximab levels-week 2 and week 6 infliximab levels were significantly lower among primary nonresponders than among responders (week 2: median infliximab level 7.2 IQR 9.3-20 lg/mL vs 13.6 IQR 2.1-15.6 lg/mL, P = .0019; week 6: median infliximab level 2.2, IQR 0.18-5.4 lg/mL vs 9.5, IQR 5.4-17.2 lg/mL, P < .0001 respectively
| CLINICAL PREDICTORS OF PRIMARY NONRESPONSE
An analysis of possible predictors of primary nonresponse was performed. The significant factors on the multivariate analyses were both week 2 and week 6 ATI levels as well as prior adalimumab therapy (P = .0002) and concomitant immunomodulator therapy (P = .01). Among the general study population, there was no difference between the study groups in baseline remission status (P = .16, Table 2 ). All univariate and multivariate analyses are detailed in Table 2 . F I G U R E 2 Patients with antibodies to infliximab (ATI) at week 2 or 6-ATI appeared more frequently among the primary nonresponders at either week 2 or 6 (prevalence of 68% vs 28%, OR = 4.6 CI 2-10.8, P = .0004) (A). Among those who developed ATI, their levels were significantly higher among primary nonresponders at both week 2 (median ATI 7.3, IQR 4.4-11.5 lg/mL-eq, vs 3.8, IQR 3-5.6 lg/mL-eq, P = .005) (B) and week 6 median ATI 10.8, IQR 6-23.8 lg/mL-eq, vs 4.4, IQR 2.8-7.2 lg/mL-eq, P = .0088 (C) F I G U R E 3 Early antibodies to infliximab (ATI) and infliximab level as predictors of response (A) Trough infliximab levels below 6.8 lg/mL at week 2 had a sensitivity of 50% and specificity of 86% for primary nonresponse (AUC = 0.68, P = .002). (B) Among ATIpositive patients, week 2 ATI levels above 4.33 lg/mL-eq had a 77% sensitivity and 71% specificity for primary nonresponse (AUC = 0.78, P = .0004)
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| 215 monotherapy, rather than combination therapy, previous CD-related surgery and older age were significantly associated with primary nonresponse. On multivariable analysis of CD patients, only week 6 drug levels (P = .01) and week 6 ATI levels (P < .0001) as well as older age (P = .05) and prior IBD-related surgery (P = .02) remained statistically significant. Among UC patients, baseline SCCAI (4, 6.5 in primary nonresponders and primary responders, IQR 2-6, 5.3-7, respectively, P = .04), monotherapy (OR 0.14, CI 0.02-0.8, P = .027), in addition to drug and ATI levels, remained significantly associated with primary nonresponse. It is of note, that as all UC patients were anti-TNF naive and only 1 patient (a primary responder) received episodic therapy, these parameters could not be assessed. Multivariate analysis was not performed due to the limited number of UC patients (n = 32). Tables S1 and S2 depict all univariate and multivariate associations among CD and UC patients respectively.
| DISCUSSION
Primary nonresponse to infliximab therapy occurs in 10%-30% of IBD patients. 10, 18 The mechanisms underlying this phenomenon are still obscure, and it is estimated that primary nonresponse can be either a pharmacokinetic process (in the presence of low drug and elevated ATI levels) or a pharmacodynamic one (with sufficient drug levels and no ATI, hence probably not TNF driven). 19 In this study, we aimed to evaluate the role of pharmacokinetics in primary nonresponse to infliximab among a "real life" cohort of IBD patients-to which extent early induction infliximab and ATI levels can predict primary nonresponse.
For both week 2 and week 6, infliximab levels were significantly lower and ATI levels were significantly higher among primary nonresponders. Several other studies evaluated early induction infliximab and ATI levels in relation to clinical outcome, however, most were of limited sample size and specific early induction period cut-offs for drug and antibody levels for response to infliximab induction therapy have not been established. All but one study identified lower drug levels and positive ATI as predictive of unfavourable clinical outcome. 9, [20] [21] [22] Recently, infliximab levels > 15, 2.1 lg/mL at weeks 2, 6 (AUC 0.69, 0.78 respectively) were associated with mucosal healing by the end of induction. 12 In our study, week 2 and week 6 levels below 6.8 and 3.5 lg/mL were associated with primary nonresponse (AUC = 0.78, 0.86 respectively). The relatively lower week 2 As infliximab drug and antibody levels are dependent variables, each was incorporated into the multivariable analysis separately for either week 2 or 6 levels.
b Baseline clinical status was based on HBI/SCCAI, determined for every patient pre-infusion.
infliximab level presented in the current study might stem from differences in assays for measurement of drug levels and ATI (although both were drug tolerant ELISA assays) as well as from different outcomes evaluated (primary nonresponse vs lack of short-term mucosal healing). Previous studies have also associated positive ATI with primary nonresponse. Specific cut-offs for ATI values have not been established. In the present study, while ATI positivity itself was predictive of nonresponse at week 6, week 2 ATI level >4.3 lg/mL-eq, rather than between 2.5 and 4.3 lg/mL-eq were associated with this outcome. These cut-off values need to be confirmed by other assays, but perhaps the notion that higher ATI levels (~twice the upper normal limit) are more specific for primary nonresponse might be of value for clinical decision-making.
It is of note that ATI formation rate was lower at week 6 than at week 2, which implies that some of the ATI detected at week 2 28 This outcome was assessed in relation to all anti-TNFs and not to infliximab specifically. The findings in our study are partially in line with those mentioned above; in addition to week 2 and week 6 drug and ATI levels, prior adalimumab therapy and monotherapy have been associated with primary nonresponse in the general cohort, whereas among CD patients, older age and prior CD-related surgeries had a statistically significant effect as well. The significant association of monotherapy, rather than combination therapy, with primary nonresponse, both among the CD and UC cohorts, strengthens the benefit of "combo-therapy", especially during induction. For UC patients, elevated baseline clinical score and pan-colitis were associated with primary nonresponse. This goes in line with previous publications stating that infliximab levels were higher in patients with acute severe colitis, in comparison with moderate-severe colitis, and that in severe colitis, infliximab levels might be lower due to a higher inflammatory burden and faecal loss. 29, 30 Our study has several limitations. Firstly, the retrospective nature of the study. Nevertheless, primary nonresponse, defined as cessation of infliximab therapy by the end of induction due to lack of clinical improvement, is an objective endpoint. In addition, all infliximab and ATI measurements were obtained prospectively, before each infusion. Next, although baseline clinical scores indicating disease severity were included, biochemical parameters of disease severity-CRP and albumin, were not assessed in this study. Moreover, the results were obtained with the extensively validated anti-lambda ELISA detection assay, but corroborating studies using other assays are pertinent as measurements may not be entirely comparable.
To conclude, this is one of the largest "real life" cohorts available of primary nonresponders to infliximab therapy, compared with primary responders. As consecutive prospective drug and antibody levels' measurements were available for all patients included, determination of pharmacokinetic cut-offs for primary nonresponse was feasible. Hence, infliximab levels below 6.8 lg/mL and ATI levels above 4.3 lg/mL-eq before the second infusion (week 2) were significantly associated with primary nonresponse. These values might assist clinicians in early prediction and prevention of primary nonresponse.
Nevertheless, a minority of primary nonresponders had high infliximab levels and no ATI at weeks 2 and 6, which hints that in some of the cases, the mechanism for primary nonresponse is not TNF-driven. 
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